日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Clinical and Economic Outcomes of Dronedarone Versus Amiodarone Among Patients With Atrial Fibrillation

胺碘酮与决奈达隆治疗房颤患者的临床和经济结果

期刊:Journal of the American Heart Association
影响因子:5.3
doi:10.1161/JAHA.125.042178
Steinberg, Benjamin A; Dabbous, Firas; Preblick, Ron; Shridharmurthy, Divya; McKindley, David S; Rashkin, Jason; Huse, Samuel; Colby, Chris; Singh, Jagmeet P
发表日期：2026
文献求助 收藏

Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study

接受基础胰岛素治疗的 2 型糖尿病患者跌倒和骨折相关的医疗资源利用和成本：FRAGILE 研究

期刊:Journal of Health Economics and Outcomes Research
影响因子:2.3
doi:10.36469/001c.133274
Umpierrez, Guillermo E; Pogge, Elizabeth K; Li, Xuan; Preblick, Ronald; Gill, Jasvinder; Pandya, Naushira
代谢
糖尿病
骨折
免疫/内分泌
发表日期：2025
文献求助 收藏

Health Care Resource Utilization With Dronedarone Versus Sotalol Following Catheter Ablation in Adults With Atrial Fibrillation

成人房颤患者导管消融术后使用决奈达隆与索他洛尔治疗的医疗资源利用情况比较

期刊:Clinical Cardiology
影响因子:2.3
doi:10.1002/clc.70064
Zeitler, Emily P; Stein, Dara; Preblick, Ron; Kabadi, Shaum M; McKindley, David S; Rashkin, Jason; Huse, Samuel; Stamas, Nicole; Kim, Michael H
发表日期：2025
文献求助 收藏

Real-World Health Care Resource Utilization and Costs Associated With First-Line Dronedarone Versus First-Line Ablation in Adults With Atrial Fibrillation

真实世界中，一线使用决奈达隆与一线消融治疗成人房颤患者的医疗资源利用情况及相关成本

期刊:Clinical Cardiology
影响因子:2.3
doi:10.1002/clc.70145
Greene, Stephen J; Schilsky, Samantha; Roberts, Andrew W; Kabadi, Shaum M; McKindley, David S; Preblick, Ron; Rashkin, Jason; Leeming, Reno C; Sajedian, Renee M; Russo, Andrea M
发表日期：2025
文献求助 收藏

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study

使用 iGlarLixi 治疗 2 型糖尿病患者的临床获益：一项患者水平模拟研究

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-023-01419-z
Chauhan, Ankita; Samnaliev, Mihail; Ken-Opurum, Jennifer; Srinivas, Sistla S S; Mehta, Aashay M; Dex, Terry; Charland, Scott; Revel, Andrew; Preblick, Ronald
糖尿病
代谢
发表日期：2023
文献求助 收藏

Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus

针对2型糖尿病患者，采用iGlarLixi强化治疗与替代治疗策略的预算影响分析

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-023-01477-3
Ken-Opurum, Jennifer; Srinivas, Sistla S S; Jain, Divya; Shah, Tejaswinee; Samnaliev, Mihail; Dex, Terry; Charland, Scott; Revel, Andrew; Preblick, Ronald
糖尿病
代谢
发表日期：2023
文献求助 收藏

A value-based budget impact model for dronedarone compared with other rhythm control strategies

与其他节律控制策略相比，胺碘酮的基于价值的预算影响模型

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2022-0196
Ken-Opurum, Jennifer; Srinivas, Sesha Ss; Vadagam, Pratyusha; Faith, Lang; Park, Seojin; Charland, Scott; Revel, Andrew; Preblick, Ronald
发表日期：2023
文献求助 收藏

Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillation

抗心律失常药物与消融术治疗房颤的临床和经济结果

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2023-0065
Ken-Opurum, Jennifer; Srinivas, Sesha Ss; Park, Seojin; Charland, Scott; Revel, Andrew; Preblick, Ronald
发表日期：2023
文献求助 收藏

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)

真实世界中 2 型糖尿病患者继续使用第二代基础胰岛素类似物甘精胰岛素 300 单位/毫升或改用第一代基础胰岛素（甘精胰岛素 100 单位/毫升或地特胰岛素 100）的持续性、依从性、低血糖和医疗资源利用情况

期刊:Clinical Diabetes
影响因子:
doi:10.2337/cd22-0096
Edelman, Steven; Goldman, Jennifer; Malone, Daniel C; Preblick, Ronald; Munaga, Kovida; Li, Xuan; Gill, Jasvinder; Gangi, Sumana
代谢
糖尿病
免疫/内分泌
发表日期：2023
文献求助 收藏

Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin

在2型糖尿病患者中，从第一代基础胰岛素换用第二代基础胰岛素（甘精胰岛素300 U/mL）与换用其他第一代基础胰岛素相比，其真实世界中的持续性、依从性、医疗资源利用情况和成本如何？

期刊:
影响因子:
doi:10.18553/jmcp.2022.21436
Wright, Eugene E Jr; Malone, Daniel C; Trujillo, Jennifer M; Gill, Jasvinder; Huse, Samuel; Li, Xuan; Zhou, Fang Liz; Preblick, Ron; Reid, Timothy
代谢
糖尿病
免疫/内分泌
发表日期：2022
文献求助 收藏